Latest Morning Briefing Stories
KFF Health News' 'What the Health?': The Supreme Court and the Abortion Pill
The Supreme Court this week heard its first abortion case since overturning Roe v. Wade in 2022, about an appeals court ruling that would dramatically restrict the availability of the abortion pill mifepristone. But while it seems likely that this case could be dismissed on a technicality, abortion opponents have more challenges in the pipeline. Meanwhile, health issues are heating up on the campaign trail, as Republicans continue to take aim at Medicare, Medicaid, and the Affordable Care Act — all things Democrats are delighted to defend. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Lauren Weber of The Washington Post join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Tony Leys, who wrote a KFF Health News-NPR “Bill of the Month” feature about Medicare and a very expensive air-ambulance ride. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
This State Isn’t Waiting for Biden To Negotiate Drug Prices
As the federal government negotiates with drugmakers to lower the price of 10 expensive drugs for Medicare patients, impatient legislators in some states are trying to go even further. Leading the pack is Colorado, where a new Prescription Drug Affordability Review Board is set to recommend an “upper payment limit” for drugs it deems unaffordable. In late […]
At Stake in Mifepristone Case: Abortion, FDA’s Authority, and Return to 1873 Obscenity Law
The end goal for a conservative Christian group’s mifepristone case before the Supreme Court: a de facto nationwide abortion ban.
A Paramedic Was Skeptical About This Rx for Stopping Repeat Opioid Overdoses. Then He Saw It Help.
For years, addiction response teams have traveled around Florida to connect people who have overdosed with resources and recovery centers. Now, a handful have a new tool in their kit: buprenorphine, which can help prevent the cravings and withdrawal symptoms that lead to more drug use.
Journalists Track Efforts to Curb the Opioid Crisis and Put Catholic Hospitals Under the Scope
KFF Health News and California Healthline staff made the rounds on national and local media in recent weeks to discuss their stories. Here’s a collection of their appearances.
KFF Health News' 'What the Health?': The ACA Turns 14
Saturday marks the 14th anniversary of the still somewhat embattled Affordable Care Act. Health and Human Services Secretary Xavier Becerra joins host Julie Rovner to discuss the accomplishments of the health law — and the challenges it still faces. Also this week, Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Mary Agnes Carey of KFF Health News join Rovner to discuss what should be the final funding bill for HHS for fiscal 2024, next week’s Supreme Court oral arguments in a case challenging abortion medication, and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
A Battle Between Drugmakers and Insurers Hits Patients in the Wallet
There’s a long-running battle between insurers and drugmakers over financial assistance programs that purport to help patients afford expensive drugs. And lately, insurers have been losing ground as lawmakers, regulators and courts weigh in. The issue is whether coupons and other copay aid many patients get from drugmakers should count toward annual insurance deductibles and […]
Watch: Many Americans Are Unaware of HIV Prevention Medication
Some Americans mistakenly believe medication to prevent HIV transmission through sex is just for certain groups such as gay men, but anyone who’s at risk for contracting HIV through sex could benefit.
When Copay Assistance Backfires on Patients
Drugmakers offer copay assistance programs to patients, but insurers are tapping into those funds, not counting the amounts toward patient deductibles. That leads to unexpected charges. But the practice is under growing scrutiny.
KFF Health News' 'What the Health?': Maybe It’s a Health Care Election After All
Health care wasn’t expected to be a major theme for this year’s elections. But as President Joe Biden and former President Donald Trump secured their respective party nominations this week, the future of both Medicare and the Affordable Care Act appears to be up for debate. Meanwhile, the cyberattack of the UnitedHealth Group subsidiary Change Healthcare continues to do damage to the companies’ finances with no quick end in sight. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kelly Henning of Bloomberg Philanthropies about a new, four-part documentary series on the history of public health, “The Invisible Shield.” Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too.
Ya hay una droga oral para la depresión postparto… pero cuesta $16,000
Abogados, defensores y reguladores están observando de cerca cómo las aseguradoras diseñarán las normas para cubrirlo.
A New $16,000 Postpartum Depression Drug Is Here. How Will Insurers Handle It?
A pill form of an effective drug for postpartum depression hit the market in December, but most insurers do not yet have a policy on when or whether they will pay for it. The hurdles to obtain its predecessor medication have advocates worried.
Colorado Isn’t Giving up on Its Drug Importation Dream
Colorado hopes to join Florida to become only the second state authorized to import prescription drugs from Canada. But they’re hitting the same hurdles: drugmakers — and the FDA. Colorado officials recently amended their 2022 importation application with the Food and Drug Administration, in the process revealing new correspondence that shows the state’s so-far fruitless […]
Why Covid Patients Who Could Most Benefit From Paxlovid Still Aren’t Getting It
Price worries, bureaucratic obstacles, and “I’m-over-covid-itis” slow uptake of a drug that’s complicated to take but often effective.
KFF Health News' 'What the Health?': The State of the Union Is … Busy
At last, Congress is getting half of its annual spending bills across the finish line, albeit five months after the start of the fiscal year. Meanwhile, President Joe Biden delivers his annual State of the Union address, an over-the-counter birth control pill is (finally) available, and controversy erupts over new public health guidelines for covid-19 isolation. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Neera Tanden, the White House domestic policy adviser, about Biden’s health agenda. Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too.
Journalists Examine Medicaid Unwinding, Farmworkers’ Mental Health, and the Big Opioid Payback
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Los amigos de un joven muerto por envenenamiento por fentanilo impulsan una ley estatal para que estudiantes de secundaria puedan llevar Narcan en sus mochilas sin riesgo de ser castigados.
How a Friend’s Death Turned Colorado Teens Into Anti-Overdose Activists
High school students in Colorado are pushing for a change they say is necessary to combat fentanyl poisoning: ensuring students can’t get in trouble for carrying the overdose reversal drug naloxone wherever they go, including at school.
An Arm and a Leg: Wait, Is Insulin Cheaper Now?
Did the price of insulin go down? It’s not quite that simple. On this episode of “An Arm and a Leg,” producer Emily Pisacreta explores recent changes to the cost of the diabetes medication.
Patients See First Savings From Biden’s Drug Price Push, as Pharma Lines Up Its Lawyers
A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.
